OMGA
Income statement / Annual
Last year (2023), Omega Therapeutics, Inc.'s total revenue was $3.09 M,
an increase of 49.25% from the previous year.
In 2023, Omega Therapeutics, Inc.'s net income was -$97.43 M.
See Omega Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
Operating Revenue |
$3.09 M
|
$2.07 M
|
$144,000.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$65.87 M |
$5.19 M |
$1.39 M |
$1.15 M |
$794,000.00 |
Gross Profit |
-$62.78 M |
-$3.12 M |
-$1.24 M |
-$1.15 M |
-$794,000.00 |
Gross Profit Ratio |
-20.29 |
-1.5 |
-8.63 |
0 |
0 |
Research and Development
Expenses |
$77.17 M
|
$80.00 M
|
$47.87 M
|
$21.06 M
|
$11.93 M
|
General & Administrative
Expenses |
$26.19 M
|
$21.82 M
|
$16.60 M
|
$6.24 M
|
$4.23 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$26.19 M
|
$21.82 M
|
$16.60 M
|
$6.24 M
|
$4.23 M
|
Other Expenses |
$0.00 |
$3.02 M |
$1.71 M |
$1.35 M |
$1.18 M |
Operating Expenses |
$103.36 M |
$104.84 M |
$66.18 M |
$28.65 M |
$17.34 M |
Cost And Expenses |
$103.36 M |
$104.84 M |
$66.18 M |
$28.65 M |
$17.34 M |
Interest Income |
$2.81 M |
$222,000.00 |
$910,000.00 |
$777,000.00 |
$595,000.00 |
Interest Expense |
$0.00 |
$222,000.00 |
$910,000.00 |
$777,000.00 |
$595,000.00 |
Depreciation &
Amortization |
$6.77 M
|
$5.19 M
|
$1.39 M
|
$1.15 M
|
$794,000.00
|
EBITDA |
-$93.49 M
|
-$97.58 M
|
-$64.64 M
|
-$27.50 M
|
-$16.55 M
|
EBITDA Ratio |
-30.22 |
-49.57 |
-449.12 |
0 |
0 |
Operating Income Ratio
|
-32.4
|
-49.57
|
-458.56
|
0
|
0
|
Total Other
Income/Expenses Net |
$2.83 M
|
$65,000.00
|
-$2.25 M
|
-$802,000.00
|
-$606,000.00
|
Income Before Tax |
-$97.43 M |
-$102.70 M |
-$68.28 M |
-$29.45 M |
-$17.95 M |
Income Before Tax Ratio
|
-31.49
|
-49.54
|
-474.17
|
0
|
0
|
Income Tax Expense |
$0.00 |
-$65,000.00 |
$882,000.00 |
$752,000.00 |
$584,000.00 |
Net Income |
-$97.43 M |
-$102.64 M |
-$69.16 M |
-$30.20 M |
-$18.53 M |
Net Income Ratio |
-31.49 |
-49.51 |
-480.29 |
0 |
0 |
EPS |
-1.8 |
-2.14 |
-1.45 |
-0.63 |
-0.39 |
EPS Diluted |
-1.8 |
-2.14 |
-1.45 |
-0.63 |
-0.39 |
Weighted Average Shares
Out |
$54.01 M
|
$47.88 M
|
$47.79 M
|
$47.84 M
|
$47.84 M
|
Weighted Average Shares
Out Diluted |
$54.01 M
|
$47.88 M
|
$47.79 M
|
$47.84 M
|
$47.84 M
|
Link |
|
|
|
|
|